Department of Vascular Medicine and Therapeutics, University of Saint-Etienne, Saint-Etienne, France.
Department of General Practice, University of Saint-Etienne, Saint-Etienne, France.
Phlebology. 2021 Jul;36(6):464-472. doi: 10.1177/0268355520982456. Epub 2021 Jan 6.
Information is lacking as to the management of patients with superficial venous thrombosis (SVT) whose profile has been excluded from trials, such as patients with active cancer, severe renal impairment, or pregnancy.
To describe the frequency and management of SVT occurring in these situations.
We retrospectively analyzed the frequency, management and evolution of all patients with isolated SVT associated with either active cancer, severe renal impairment, or pregnant or postpartum women, diagnosed in 2 university hospital between January 1st, 2015 and December 31st, 2016.
Of the 594 isolated SVTs individualized from the 7941 reports screened, 149 SVTs (105 in the upper extremity, 44 in the lower extremity) were analyzed: 94 (63%) associated with active cancer, 27 (18%) with severe renal impairment and 30 (20%) pregnant or postpartum women. SVT was treated with anticoagulant in 34 (36%) patients with cancer, 3 (11%) patients with severe renal impairment and 19 (63%) pregnant or postpartum women. At 3-month, 16 patients (10.8%) had a further venous thromboembolic event, 8 (5.4%) major bleeding, and 9 (6.1%) died.
SVT in patients with active cancer, severe renal impairment and pregnant or postpartum women represents a quarter of isolated SVTs diagnosed. Heterogeneity of treatment patterns mainly affects patients with cancer and severe renal impairment. Poor outcomes, although probably linked to morbidity, call for dedicated research in these specific situations.
缺乏信息来管理那些被排除在临床试验之外的浅静脉血栓形成(SVT)患者,例如患有活动性癌症、严重肾功能损害或妊娠的患者。
描述这些情况下发生的 SVT 的频率和管理。
我们回顾性分析了 2015 年 1 月 1 日至 2016 年 12 月 31 日期间在 2 所大学医院诊断的患有活动性癌症、严重肾功能损害或妊娠或产后女性的孤立性 SVT 患者的频率、管理和演变。
在从筛选的 7941 份报告中个体化的 594 例孤立性 SVT 中,分析了 149 例 SVT(94 例在上肢,44 例在下肢):94 例(63%)与活动性癌症相关,27 例(18%)与严重肾功能损害相关,30 例(20%)为妊娠或产后女性。在 34 例癌症患者(36%)、3 例严重肾功能损害患者(11%)和 19 例妊娠或产后女性(63%)中,SVT 接受了抗凝治疗。在 3 个月时,16 例患者(10.8%)发生了进一步的静脉血栓栓塞事件,8 例(5.4%)发生了大出血,9 例(6.1%)死亡。
患有活动性癌症、严重肾功能损害和妊娠或产后的 SVT 患者占诊断为孤立性 SVT 的四分之一。治疗模式的异质性主要影响癌症和严重肾功能损害患者。尽管可能与发病率有关,但不良结局需要在这些特定情况下进行专门研究。